RTI SURGICAL, INC. (NASDAQ:RTIX) Files An 8-K Regulation FD Disclosure

RTI SURGICAL, INC. (NASDAQ:RTIX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

On January5, 2018, RTI Surgical, Inc. (the “Company”) issued a press release outlining the Company’s 2018 guidance and long-term financial goals. A copy of this press release is furnished as Exhibit 99.1 to this Current Report and is incorporated in this Current Report by reference.

Company representatives will attend J.P. Morgan’s 36th Annual Health Care Conference from January8, 2018, to January11, 2018. During the conference, the Company will provide certain information to potential investors. A copy of this information is furnished as Exhibit 99.2 to this Current Report and is incorporated in this Current Report by reference.

The information furnished to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information furnished to Item 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing.

Item 7.01. Financial Statements and Exhibits.

(d) Exhibits.


RTI SURGICAL, INC. Exhibit
EX-99.1 2 d520185dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Press Release    RTI Surgical Outlines 2018 Guidance and Long-Term Goals Strategic Transformation Accelerating to Produce Long-Term Growth,…
To view the full exhibit click here

About RTI SURGICAL, INC. (NASDAQ:RTIX)

RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.

An ad to help with our costs